Method of diagnosis of non-alcoholic fatty liver diseases

a non-alcoholic fatty liver and disease technology, applied in the direction of instruments, ict adaptation, material analysis, etc., can solve the problems of not being widely adopted, not being able to detect patients, and not being able to perform liver biopsy in such a large number of patients with metabolic risk factors, etc., to improve auroc, increase specificity and sensitivity, the effect of improving the sensitivity of the tes

Pending Publication Date: 2019-08-29
BIOPREDICTIVE +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

In this patented method, we found that increasing the sensitivity of certain types of liver diseases can be achieved through the use of a combination of different techniques such as ballooning or lobular inflammatory processes. This results in more accurate diagnosis and treatment options for patients with NASH compared to other conditions like alcoholic cirrhosis.

Problems solved by technology

How to accurately diagnose and evaluate the severity of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in patients with metabolic syndrome, without the need for liver biopsy? Can the current non-invasive diagnostic testing meet this requirement? How to solve the problem of possible diagnostic errors when other liver diseases coexist?

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of diagnosis of non-alcoholic fatty liver diseases
  • Method of diagnosis of non-alcoholic fatty liver diseases
  • Method of diagnosis of non-alcoholic fatty liver diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

SAF Score and FLIP Algorithm

[0262]The classification was performed according to the following criteria, with the following paragraphs directly extracted from Bedossa et al (Hepatology, April 2014; August; 60(2):565-75; doi: 10.1002 / hep.27173).

[0263]For each biopsy a SAF score (Steatosis, Activity, Fibrosis) summarizing the main histological lesions was defined. This assesses both and separately the grade of steatosis (S), the grade of activity (A) and the stage of fibrosis (F), the latter according to NASH CRN (Kleiner et al Hepatology 2005; 41:1313-1321)

[0264]Steatosis was assessed by the percentage of hepatocytes containing large and medium-sized intracytoplasmic lipid droplets (but not foamy microvesicles), on a scale of 0 to 3 (S0: 67%).

[0265]Ballooning of hepatocytes was graded from 0 to 2 (0: normal hepatocytes with cuboidal shape, sharp angles and pink eosinophilic cytoplasm; 1: presence of clusters of hepatocytes with a rounded shape and pale cytoplasm, usually reticulated wh

example 2

gy for Developing the NASH-Non-Invasive Test

[0270]Recent simplified histological references were used for constructing new NITs, with modifications of these references due to the risk of sampling errors.

[0271]All histological scores were made according to the SAF classification as disclosed above.

[0272]For the binary histological diagnosis of NASH, it was decided to focus on ballooning and lobular inflammation, the specific features of necro-inflammatory histological activity as suggested by the histological FLIP algorithm. (Bedossa et al. Hepatology 2012, and Bedossa et al. Hepatology 2014).

[0273]It was indeed considered that the original FLIP algorithm has several limitations, the arbitrary choice of 5% of hepatocytes steatosis defining presence of steatosis, the exclusion of cases without steatosis for the diagnostic of NASH despite the severe activity grades, and the arbitrary choice of requiring both ballooning and lobular inflammation even if one of this feature reached a grade 2

example 3

ion of the NIT-Algorithm for the Diagnosis of NASH Choice of the Markers to Use in these NITs

[0282]It was decided to use ALT, AST, that are known biomarkers of liver necrosis, as well as eight other liver components synthetized by the liver: apolipoprotein A1 (apoA1), haptoglobin, alpha-2-macroglobulin, total bilirubin, GGT, triglycerides, total cholesterol, fasting glucose and three patients characteristics (age, sex, and BMI).

[0283]Other markers could be equally used in the procedure herein described, such as markers that have been described in other liver NITs. One could cite γ-globulin, albumin, α1-globulin, α2-globulin, β-globulin, IL10, TGF-β1, apoA2, apoB, cytokeratin 18 and cytokeratin 19 components, platelets number, prothrombin level, hyaluronic acid, urea, N-terminal of type III pro-collagen, Tissue inhibitor metalloproteinase type-1 (TIMP-1), type IV collagen (Coll IV) and osteoprotegerin.

[0284]However, it was decided to use only the 13 elements as mentioned above, as the r

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to new methods for assessing NAFLD and NAH in a patient, combining measurement of serum markers through a logistic function.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner BIOPREDICTIVE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products